Video: BVXP FY results interivew - October 2016

Friday, Nov 04 2016 by

This interview with Peter Harrison, CEO, Bioventix (LON:BVXP), was done around publication of FY results (YE 30.6.16), in October 2016.

Length: c 20 mins

Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange.

He goes on to talk about the NT proBNP licence, which comes to an end July 2017, with all revenue (c.£750k) being lost from August 2017 onward. Peter is confident Troponin, will launch at some point in 2017, based on all the updates given by Siemens, although timing is in Siemen’s hand. He has estimated July 2017 to start roll-out, it being the mid point of the year. He mentions the initial and on-going revenue expectations for Troponin.

Peter briefly discusses other antibodies already producing revenue, and future developments for the medium term. Cardinor, Norway is not discussed, since this is unlikely to result in revenues over the near term.

Peter answers questions on a few potential threats, including consolidation of customers and any new technologies that could disrupt their market.

Finally, he talks about staff motivation, and financial reward.

On the same link, there is a separate video clip, c. 6 mins which describes what the company does.

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way


As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. The author may own shares in any companies discussed, all opinions are his/her own & are general/impersonal. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.

Do you like this Post?
4 thumbs up
0 thumbs down
Share this post with friends

Bioventix PLC is a United Kingdom-based biotechnology company. The principal activity of the Company is the development and supply of antibodies. The Company specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The Company offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The Company offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. It sells its products through direct sales and through distributors. more »

LSE Price
Mkt Cap (£m)
P/E (fwd)
Yield (fwd)

  Is LON:BVXP fundamentally strong or weak? Find out More »

Please subscribe to submit a comment

Stock Picking Tutorial Centre

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis